Cibus, Inc.
NASDAQ:CBUSBiotechnology
+$0.04 today
- Market cap
- $104.71M
- Beta
- 1.65
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.16
Volume 0.25M
Average 0.51M
CBUS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Cibus, Inc.NASDAQ: CBUS
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 28.6% from a year ago
Cash & equivalents stood at $30.33M at the end of Q1 FY2026, up 28.6% from a year earlier and up 205.6% from the prior quarter. Over 3 fiscal years it compounded at +42.5% a year.
Context
- Cash & equivalents amounted to 9.4% of total assets at the end of Q1 FY2026, up 2.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +28.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 9.92M USD
- Year-over-year change
- -31.2%
- 4-year CAGR
- -8.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.92M | -31.2% |
| FY2024 | 2024-12-31 | 14.43M | -55.9% |
| FY2023 | 2023-12-31 | 32.7M | +854.2% |
| FY2022 | 2022-12-31 | 3.43M | -75.2% |
| FY2021 | 2021-12-31 | 13.82M | — |
Cash & Equivalents vs competitors
How CBUS compares with its peers on the latest reported figures
- CBUS's Mar 2026 cash & equivalents of $30.33M is the 8th highest of the 10 companies compared; the peer median is $39.13M.
- Its year-over-year change of +28.6% is the 6th highest of 10, against a peer median of +76.8%.
- Cash & equivalents amounts to 9.4% of total assets for CBUS, versus a peer median of 58.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $186.63M | +1204.7% | -47.5% | 98.4% | |
| Mar 2026 | $99.21M | +101.1% | — | 94.1% | |
| Mar 2026 | $50.75M | +76.8% | +6.9% | 28.2% | |
| Mar 2026 | $44.69M | +24.6% | -20.7% | 96.4% | |
| Mar 2026 | $39.13M | -23.8% | -29.5% | 40.5% | |
| Mar 2026 | $37.37M | +89.0% | +300.4% | 58.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M | -13.0% | +12.0% | 31.6% |
CBUSCibus, Inc. | Mar 2026 | $30.33M | +28.6% | +42.5% | 9.4% |
| Mar 2026 | $27.33M | -25.3% | +18.5% | 64.0% | |
| Mar 2026 | $9.78M | +750.3% | -13.5% | 4.2% | |
| Peer median (excluding CBUS) | $39.13M | +76.8% | -3.3% | 58.0% | |
Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13.82M | 3.43M | 32.7M | 14.43M | 9.92M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 530K | 1.04M | 703K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 499K | 705K | 1.99M | 1.47M | 1.44M |
| Total Current Assets | 15.18M | 4.13M | 35.22M | 16.95M | 12.07M |
| Property, Plant & Equipment (Net) | 21.73M | 18.13M | 37.46M | 44.69M | 27.86M |
| Goodwill | 0 | 0 | 434.9M | 253.47M | 232.52M |
| Intangible Assets | 0 | 158K | 35.41M | 33.58M | 31.68M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 282K | 0 | 1.42M | 1.39M | 926K |
| Total Non-current Assets | 22.01M | 18.29M | 509.19M | 333.12M | 292.98M |
| Total Assets | 37.19M | 22.42M | 544.41M | 350.07M | 305.05M |
| Account Payables | 1.26M | 340K | 6.13M | 5.96M | 8.07M |
| Short-term Debt | 0 | 0 | 833K | 436K | 3.17M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 107K | 1.21M | 932K | 536K |
| Other Current Liabilities | 2.71M | 403K | 5.29M | 5.87M | 5.09M |
| Total Current Liabilities | 4.85M | 1.66M | 21.32M | 19.88M | 16.86M |
| Long-term Debt | 0 | 0 | 536K | 226K | 235.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 702K | 79K | 167.12M | 200.91M | 1.56M |
| Total Non-current Liabilities | 18.21M | 13.53M | 184.79M | 232.36M | 266.36M |
| Total Liabilities | 23.06M | 15.19M | 206.12M | 252.24M | 283.22M |
| Common Stock | 4K | 5K | 8K | 9K | 79K |
| Retained Earnings | (196.09M) | (212.15M) | (479.78M) | (731.17M) | (858.25M) |
| Accumulated OCI | 0 | 0 | 8K | 15K | 39K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 44.82M | 5.67M | 0 |
| Total Equity | 14.13M | 7.23M | 338.29M | 97.83M | 21.83M |
| Total Debt | 17.88M | 13.91M | 24.62M | 36.29M | 267.96M |
| Net Debt | 4.05M | 10.48M | (8.08M) | 21.85M | 258.04M |
Cibus, Inc.
NASDAQ:CBUS
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.